Table 4.
Immunohistochemical Analysis of ATC and PDTC Tissue Samples 1 | Imaging Analysis 2 | |||||
---|---|---|---|---|---|---|
Metastatic Side | No PSMA Expression | PSMA-Labelling Index 1 “Low Expression” |
PSMA-Labelling Index 2 “Strong Expression” |
PSMA-Labelling Index 3 “Strong Expresion” |
Clearly PSMA-Positive Lesions/Total Rated Lesions | Discreet PSMA-Positive Lesions/Total Rated Lesions |
ATC | ||||||
Pulmonary/pleural metastases (n = 1) | 0 | 0 | 1 | 0 | 0/2 | 0/2 |
PDTC | ||||||
Cervical lymph node metastases (n = 2) | 0 | 1 | 1 | 0 | 0/2 | 1/2 |
Pulmonary metastases (n = 1) | 0 | 1 | 0 | 0 | 0/>10 | 0/>10 |
Local recurrence (n = 1) | 0 | 1 | 0 | 0 | 0/1 | 0/1 |
Osseous metastases (n = 1) | 0 | 0 | 1 | 0 | 0/>10 | 0/>10 |
1 PSMA-labelling index 1, “low expression”: weak or moderate staining intensity in <5% of the neovasculature.—weak staining intensity in >5% of the neovasculature. PSMA-labelling index 2, “strong expression”: moderate staining intensity in >5% of the neovasculature.—strong staining intensity < or >5% of the neovasculature. PSMA-labelling index 3, “strong expression”: strong staining intensity not only in the neovasculature, but also in the tumor cells. 2 For explanation refer to Table 3.